Tommy Martinsson

List of Publications by Year
in descending order

216	8,258	38742 50	62596 80
papers	citations	h-index	g-index

228	228	228	8480
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Sustained Response to Entrectinib in an Infant With a Germline ALKAL2 Variant and Refractory Metastatic Neuroblastoma With Chromosomal 2p Gain and Anaplastic Lymphoma Kinase and Tropomyosin Receptor Kinase Activation. JCO Precision Oncology, 2022, 6, e2100271.	3.0	8
2	The loss of DLG2 isoform 7/8, but not isoform 2, is critical in advanced staged neuroblastoma. Cancer Cell International, 2021, 21, 170.	4.1	4
3	Frequency and Prognostic Impact of ALK Amplifications and Mutations in the European Neuroblastoma Study Group (SIOPEN) High-Risk Neuroblastoma Trial (HR-NBL1). Journal of Clinical Oncology, 2021, 39, 3377-3390.	1.6	30
4	Single-nuclei transcriptomes from human adrenal gland reveal distinct cellular identities of low and high-risk neuroblastoma tumors. Nature Communications, 2021, 12, 5309.	12.8	38
5	High Expression of PPM1D Induces Tumors Phenotypically Similar to TP53 Loss-of-Function Mutations in Mice. Cancers, 2021, 13, 5493.	3.7	6
6	PPM1D Is a Therapeutic Target in Childhood Neural Tumors. Cancers, 2021, 13, 6042.	3.7	5
7	A genomeâ€‘wide scan to locate regions associated with familial vesicoureteral reflux. Experimental and Therapeutic Medicine, 2021, 23, 92.	1.8	0
8	Analysis of ALK, MYCN, and the ALK ligand ALKAL2 (FAM150B/AUGÎ±) in neuroblastoma patient samples with chromosome arm 2p rearrangements. Genes Chromosomes and Cancer, 2020, 59, 50-57.	2.8	18
9	11q Deletion or ALK Activity Curbs DLG2 Expression to Maintain an Undifferentiated State in Neuroblastoma. Cell Reports, 2020, 32, 108171.	6.4	25
10	Age Dependency of the Prognostic Impact of Tumor Genomics in Localized Resectable MYCN-Nonamplified Neuroblastomas. Report From the SIOPEN Biology Group on the LNESG Trials and a COG Validation Group. Journal of Clinical Oncology, 2020, 38, 3685-3697.	1.6	9
11	Whole-genome sequencing of recurrent neuroblastoma reveals somatic mutations that affect key players in cancer progression and telomere maintenance. Scientific Reports, 2020, 10, 22432.	3.3	19
12	Low Frequency ALK Hotspots Mutations In Neuroblastoma Tumours Detected By Ultra-deep Sequencing: Implications For ALK Inhibitor Treatment. Scientific Reports, 2019, 9, 2199.	3.3	14
13	Familial intestinal degenerative neuropathy with chronic intestinal pseudo-obstruction linked to a gene locus with duplication in chromosome 9. Scandinavian Journal of Gastroenterology, 2019, 54, 1441-1447.	1.5	3
14	Abstract 1692: Genomic changes in relapsed neuroblastoma. , 2019, , .		0
15	Sense-Antisense lncRNA Pair Encoded by Locus 6p22.3 Determines Neuroblastoma Susceptibility via the USP36-CHD7-SOX9 Regulatory Axis. Cancer Cell, 2018, 33, 417-434.e7.	16.8	122
16	Patient-Derived Xenograft Models Reveal Intratumor Heterogeneity and Temporal Stability in Neuroblastoma. Cancer Research, 2018, 78, 5958-5969.	0.9	40
17	Clinical response of the novel activating ALK-I1171T mutation in neuroblastoma to the ALK inhibitor ceritinib. Journal of Physical Education and Sports Management, 2018, 4, a002550.	1.2	47
18	Abstract 2246: Identification of mutational signatures in high-risk neuroblastoma patients. , 2018, , .		1

#	Article	IF	Citations
19	Abstract 3185: Whole genome sequencing for precision medicine in high-risk neuroblastoma patients: Translation from research to clinical practice in Sweden. , 2018, , .		0
20	Abstract B27: Anaplastic lymphoma kinase addicted neuroblastoma cell lines are associated with growth upon treatment with MEK inhibitor trametinib. , 2018, , .		0
21	Rho-associated kinase is a therapeutic target in neuroblastoma. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E6603-E6612.	7.1	52
22	MEK inhibitor trametinib does not prevent the growth of anaplastic lymphoma kinase (ALK)â€“addicted neuroblastomas. Science Signaling, 2017, 10, .	3.6	41
23	A new GTF2I-BRAF fusion mediating MAPK pathway activation in pilocytic astrocytoma. PLoS ONE, 2017, 12, e0175638.	2.5	27
24	Abstract 1945: PPM1D/Wip1, promising new target in childhood cancers neuroblastoma and medulloblastoma. , 2017, , .		0
25	Abstract 4876: Low frequent ALK hotspot mutations in neuroblastoma tumors detected by ultra deep sequencing: Implications for ALK inhibitor treatment. , 2017, , .		0
26	Abstract 1937: Evolution of neuroblastoma patient-derived orthotopic xenografts through space and time. , 2017, , .		0
27	Abstract 4867: Exome- and whole genome sequencing for clinical evaluation and precision medicine in neuroblastoma. , 2017, , .		0
28	Abstract B40: A novel activating I1171T ALK mutation in neuroblastoma responds better to ceritinib compare to the first generation inhibitor crizotinib. , 2017, , .		0
29	The ALK inhibitor PF-06463922 is effective as a single agent in neuroblastoma driven by expression of ALK and MYCN. DMM Disease Models and Mechanisms, 2016, 9, 941-52.	2.4	62
30	The genetic tumor background is an important determinant for heterogeneous MYCNâ€amplified neuroblastoma. International Journal of Cancer, 2016, 139, 153-163.	5.1	32
31	Genome-wide methylation profiling identifies novel methylated genes in neuroblastoma tumors. Epigenetics, 2016, 11, 74-84.	2.7	63
32	Estimation of copy number aberrations: Comparison of exome sequencing data with SNP microarrays identifies homozygous deletions of 19q13.2 and CIC in neuroblastoma. International Journal of Oncology, 2016, 48, 1103-1116.	3.3	18
33	The 1p36 Tumor Suppressor KIF 1Bβ Is Required for Calcineurin Activation, Controlling Mitochondrial Fission and Apoptosis. Developmental Cell, 2016, 36, 164-178.	7.0	32
34	Comparative genetic study of intratumoral heterogenous MYCN amplified neuroblastoma versus aggressive genetic profile neuroblastic tumors. Oncogene, 2016, 35, 1423-1432.	5.9	27
35	Abstract 2430: Neuroblastoma: Telomere elongation is responsible for aggressive behavior. , 2016, , .		0
36	Abstract 2435: Amplification of CDK4 and MDM2 is associated with atypical clinical features in high risk neuroblastoma patients. , 2016, , .		0

#	Article	IF	Citations
37	Exome Sequencing of an Adult Pituitary Atypical Teratoid Rhabdoid Tumor. Frontiers in Oncology, 2015, 5, 236.	2.8	17
38	Influence of segmental chromosome abnormalities on survival in children over the age of 12 months with unresectable localised peripheral neuroblastic tumours without MYCN amplification. British Journal of Cancer, 2015, 112, 290-295.	6.4	39
39	COX/mPGES-1/PGE ₂ pathway depicts an inflammatory-dependent high-risk neuroblastoma subset. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 8070-8075.	7.1	88
40	Intragenic anaplastic lymphoma kinase (ALK) rearrangements: Translocations as a novel mechanism of ALK activation in neuroblastoma tumors. Genes Chromosomes and Cancer, 2015, 54, 99-109.	2.8	45
41	Abstract 4831: Analysis of genetic variations in neuroblastoma using deep targeted sequencing. , 2015, , .		0
42	Abstract 495: Amplification of chromosomal regions 12q13-14 and 12q15 defines a distinct subgroup of high-risk neuroblastoma patients and is associated with atypical clinical features. , 2015, , .		0
43	Abstract 503: The PPM1D encoded phosphatase Wip1 is a novel oncogene and potential therapeutic target in neuroblastoma and medulloblastoma. , 2015, , .		0
44	Abstract 3266: Inhibition of Rho-associated kinase 2 suppresses MYCN expression and induces differentiation of neuroblastoma. , 2015, , .		0
45	RNA Helicase A Is a Downstream Mediator of KIF1BÎ² Tumor-Suppressor Function in Neuroblastoma. Cancer Discovery, 2014, 4, 434-451.	9.4	48
46	Emergence of New ALK Mutations at Relapse of Neuroblastoma. Journal of Clinical Oncology, 2014, 32, 2727-2734.	1.6	176
47	423 RNA helicase A is essential for 1p36 gene KIF1BÎ² tumor suppression in neuroblastomas. European Journal of Cancer, 2014, 50, 135.	2.8	0
48	Deletion of the MGMT gene in familial melanoma. Genes Chromosomes and Cancer, 2014, 53, 703-711.	2.8	4
49	The Risk-Associated Long Noncoding RNA NBAT-1 Controls Neuroblastoma Progression by Regulating Cell Proliferation and Neuronal Differentiation. Cancer Cell, 2014, 26, 722-737.	16.8	287
50	Neuroblastoma after Childhood: Prognostic Relevance of Segmental Chromosome Aberrations, ATRX Protein Status, and Immune Cell Infiltration. Neoplasia, 2014, 16, 471-480.	5.3	25
51	A mutation in POLE predisposing to a multi-tumour phenotype. International Journal of Oncology, 2014, 45, 77-81.	3.3	61
52	Emergence of new ALK mutations at relapse of neuroblastoma.. Journal of Clinical Oncology, 2014, 32, 11006-11006.	1.6	0
53	Abstract 3971: PPM1D/WIP1, a potential target in neuroblastoma. , 2014, , .		0
54	Abstract 5082: Whole-exome sequencing of an adult pituitary atypical teratoid rhabdoid tumor (AT/RT) - A not so simple genome as pediatric AT/RT. , 2014, , .		0

#	Article	IF	Citations
55	Abstract 3108: Copy number variation analysis in neuroblastoma through next generation sequencing data and SNP-microarray. , 2014, , .		0
56	Abstract B56: Genomic background of neuroblastomas with intratumor heterogeneity of MYCN amplification. , 2014, , .		0
57	Aggressive neuroblastomas have high p110alpha but low p110delta and p55alpha/p50alpha protein levels compared to low stage neuroblastomas. Journal of Molecular Signaling, 2013, 8, 4.	0.5	4
58	Age dependence of tumor genetics in unfavorable neuroblastoma: arrayCGH profiles of 34 consecutive cases, using a Swedish 25-year neuroblastoma cohort for validation. BMC Cancer, 2013, 13, 231.	2.6	9
59	Aneuploidy in neuroblastoma tumors is not associated with inactivating point mutations in the STAG2 gene. BMC Medical Genetics, 2013, 14, 102.	2.1	5
60	P.16.13 Myopathy with typical OPMD morphology without association with the PABPN1 gene locus. Neuromuscular Disorders, 2013, 23, 826.	0.6	0
61	Constitutional 11q14-q22 chromosome deletion syndrome in a child with neuroblastoma MYCN single copy. European Journal of Medical Genetics, 2013, 56, 626-634.	1.3	12
62	Cell culture andDrosophilamodel systems define three classes of anaplastic lymphoma kinase mutations in neuroblastoma. DMM Disease Models and Mechanisms, 2013, 6, 373-82.	2.4	59
63	The microenvironment of human neuroblastoma supports the activation of tumor-associated T lymphocytes. OncoImmunology, 2013, 2, e23618.	4.6	32
64	Frequent detection of human cytomegalovirus in neuroblastoma: A novel therapeutic target?. International Journal of Cancer, 2013, 133, 2351-2361.	5.1	62
65	Stage-dependent expression of PI3K/Akt-pathway genes in neuroblastoma. International Journal of Oncology, 2013, 42, 609-616.	3.3	19
66	Genetic Instability and Intratumoral Heterogeneity in Neuroblastoma with MYCN Amplification Plus 11q Deletion. PLoS ONE, 2013, 8, e53740.	2.5	33
67	Abstract 3817: The potential oncogenic significance of Wip1 in neuroblastoma.. , 2013, , .		0
68	Hereditary myopathy with early respiratory failure associated with a mutation in A-band titin. Brain, 2012, 135, 1682-1694.	7.6	95
69	Quantitative global and gene-specific promoter methylation in relation to biological properties of neuroblastomas. BMC Medical Genetics, 2012, 13, 83.	2.1	20
70	The RASSF gene family members RASSF5, RASSF6 and RASSF7 show frequent DNA methylation in neuroblastoma. Molecular Cancer, 2012, 11, 40.	19.2	69
71	Anaplastic Lymphoma Kinase (ALK) regulates initiation of transcription of MYCN in neuroblastoma cells. Oncogene, 2012, 31, 5193-5200.	5.9	103
72	G.O.2 Hereditary myopathy with early respiratory failure associated with a mutation in A-band titin. Neuromuscular Disorders, 2012, 22, 873.	0.6	0

#	Article	IF	Citations
73	High-resolution copy number array in the molecular cytogenetic diagnostics of pediatric malignant hematological disorders. Oncology Reports, 2012, 27, 1429-34.	2.6	1
74	Tumor Development, Growth Characteristics and Spectrum of Genetic Aberrations in the TH-MYCN Mouse Model of Neuroblastoma. PLoS ONE, 2012, 7, e51297.	2.5	43
75	Abstract 2499: The significance of Wip1 in neuroblastoma and medulloblastoma. , 2012, , .		0
76	Abstract 2237: Analysis of the PI3K/Akt signaling pathway in neuroblastoma shows stage dependent expression of PI3K isoforms. , 2012, , .		1
77	MYCN-regulated miRNA-92 inhibits secretion of the tumor suppressor DICKKOPF-3 (DKK3) in neuroblastoma. Carcinogenesis, 2011, 32, 1005-1012.	2.8	67
78	MYCN amplicon junctions as tumor-specific targets for minimal residual disease detection in neuroblastoma. International Journal of Oncology, 2011, 39, 1063-71.	3.3	7
79	Identification of epigenetically regulated genes that predict patient outcome in neuroblastoma. BMC Cancer, 2011, 11, 66.	2.6	67
80	Comprehensive SNP array study of frequently used neuroblastoma cell lines; copy neutral loss of heterozygosity is common in the cell lines but uncommon in primary tumors. BMC Genomics, 2011, 12, 443.	2.8	33
81	Alternative lengthening of telomeresâ€"An enhanced chromosomal instability in aggressive nonâ€MYCN amplified and telomere elongated neuroblastomas. Genes Chromosomes and Cancer, 2011, 50, 250-262.	2.8	34
82	Appearance of the Novel Activating F1174S ALK Mutation in Neuroblastoma Correlates with Aggressive Tumor Progression and Unresponsiveness to Therapy. Cancer Research, 2011, 71, 98-105.	0.9	80
83	A Multilocus Technique for Risk Evaluation of Patients with Neuroblastoma. Clinical Cancer Research, 2011, 17, 792-804.	7.0	39
84	High-risk neuroblastoma tumors with 11q-deletion display a poor prognostic, chromosome instability phenotype with later onset. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 4323-4328.	7.1	200
85	Fructose 1,6â€bisphosphatase deficiency: enzyme and mutation analysis performed on calcitriolâ€stimulated monocytes with a note on longâ€term prognosis. Journal of Inherited Metabolic Disease, 2010, 33, 113-121.	3.6	33
86	P2.14 Familial myopathy with early respiratory failure and sharing of a large haplotype at chromosome 2q31. Neuromuscular Disorders, 2010, 20, 622.	0.6	0
87	Meta-analysis of Neuroblastomas Reveals a Skewed ALK Mutation Spectrum in Tumors with MYCN Amplification. Clinical Cancer Research, 2010, 16, 4353-4362.	7.0	243
88	MHC Class II Deficiency. , 2009, , 1306-1308.		0
89	Germline mutation screening of the Saethre-Chotzen-associated genesTWIST1andFGFR3in families withBRCA1/2-negative breast cancer. Scandinavian Journal of Plastic and Reconstructive Surgery and Hand Surgery, 2009, 43, 251-255.	0.6	1
90	Germline mutation in the FGFR3 gene in a TWIST1â€negative family with saethreâ€chotzen syndrome and breast cancer. Genes Chromosomes and Cancer, 2009, 48, 285-288.	2.8	15

#	Article	IF	Citations
91	Verification of genes differentially expressed in neuroblastoma tumours: a study of potential tumour suppressor genes. BMC Medical Genomics, 2009, 2, 53.	1.5	24
92	The Phox2 pathway is differentially expressed in neuroblastoma tumors, but no mutations were found in the candidate tumor suppressor gene PHOX2A. International Journal of Oncology, 2009, 34, 697-705.	3.3	12
93	High-resolution array copy number analyses for detection of deletion, gain, amplification and copy-neutral LOH in primary neuroblastoma tumors: Four cases of homozygous deletions of the CDKN2A gene. BMC Genomics, 2008, 9, 353.	2.8	84
94	Methotrexate resistance and double minutes in a cell line from the SEWA mouse ascites tumor. Hereditas, 2008, 97, 123-137.	1.4	20
95	Transfer of methotrexate resistance by somatic cell hybridization. Hereditas, 2008, 99, 293-302.	1.4	10
96	Isolation of selectively amplified DNA sequences from multidrug-resistant SEWA cells. Hereditas, 2008, 106, 97-105.	1.4	9
97	Amplification and overexpression of the P-glycoprotein genes and differential amplification of three other genes in SEWA murine multidrug-resistant cells. Hereditas, 2008, 108, 251-258.	1.4	18
98	An improved technique for chromosome preparations from human lymphocytes. Hereditas, 2008, 115, 295-297.	1.4	14
99	High incidence of DNA mutations and gene amplifications of the ALK gene in advanced sporadic neuroblastoma tumours. Biochemical Journal, 2008, 416, 153-159.	3.7	246
100	Analysis of neuroblastoma tumour progression; loss of PHOX2B on 4p13 and 17q gain are early events in neuroblastoma tumourigenesis. International Journal of Oncology, 2008, , .	3.3	5
101	Genetic and epigenetic changes in the common 1p36 deletion in neuroblastoma tumours. British Journal of Cancer, 2007, 97, 1416-1424.	6.4	52
102	1409 POSTER Differential expressed genes in favourable versus unfavourable neuroblastoma tumors. European Journal of Cancer, Supplement, 2007, 5, 180.	2.2	0
103	Neuroblastoma tumors with favorable and unfavorable outcomes: Significant differences in mRNA expression of genes mapped at 1p36.2. Genes Chromosomes and Cancer, 2007, 46, 45-52.	2.8	31
104	Genome-wide linkage scan for breast cancer susceptibility loci in Swedish hereditary non-BRCA1/2 families: Suggestive linkage to 10q23.32-q25.3. Genes Chromosomes and Cancer, 2007, 46, 302-309.	2.8	18
105	Inverse relation between nasal fluid Clara Cell Protein 16 levels and symptoms and signs of rhinitis in allergen-challenged patients with intermittent allergic rhinitis. Allergy: European Journal of Allergy and Clinical Immunology, 2007, 62, 178-83.	5.7	37
106	Occurrence of both breast and ovarian cancer in a woman is a marker for the BRCA gene mutations: a population-based study from Western Sweden. Familial Cancer, 2007, 6, 35-41.	1.9	15
107	The two human homologues of yeast UFD2 ubiquitination factor, UBE4A and UBE4B, are located in common neuroblastoma deletion regions and are subject to mutations in tumours. European Journal of Cancer, 2006, 42, 381-387.	2.8	25
108	Mutations and sequence variation in the human myosin heavy chain IIa gene (MYH2). European Journal of Human Genetics, 2005, 13, 617-622.	2.8	32

#	Article	IF	Citations
109	Introduction of in vitro transcribed ENO1 mRNA into neuroblastoma cells induces cell death. BMC Cancer, 2005, 5, 161.	2.6	62
110	A high frequency of germline BRCA1/2 mutations in western Sweden detected with complementary screening techniques. Familial Cancer, 2005, 4, 89-96.	1.9	23
111	Collecting a set of psoriasis family material through a patient organisation; clinical characterisation and presence of additional disorders. BMC Dermatology, 2005, 5, 10.	2.1	19
112	Imbalance of the mitochondrial pro- and anti-apoptotic mediators in neuroblastoma tumours with unfavourable biology. European Journal of Cancer, 2005, 41, 635-646.	2.8	33
113	A cluster of genes located in 1p36 are down-regulated in neuroblastomas with poor prognosis, but not due to CpG island methylation. Molecular Cancer, 2005, 4, 10.	19.2	35
114	Increased recurrence risk in congenital disorders of glycosylation type Ia (CDG-Ia) due to a transmission ratio distortion. Journal of Medical Genetics, 2004, 41, 877-880.	3.2	21
115	Mutations in the N-terminal domain of DFF45 in a primary germ cell tumor and in neuroblastoma tumors. International Journal of Oncology, 2004, 25, 1297.	3.3	10
116	Hereditary multiple and isolated sporadic exostoses in the same kindred: Identification of the causative gene (EXT2) and detection of a new mutation, nt112delAT, that distinguishes the two phenotypes. International Journal of Molecular Medicine, 2004, 13, 47.	4.0	1
117	DNA microarray analysis of chromosomal susceptibility regions to identify candidate genes for allergic disease: A pilot study. Acta Oto-Laryngologica, 2004, 124, 813-819.	0.9	4
118	SLIT2 promoter methylation analysis in neuroblastoma, Wilms' tumour and renal cell carcinoma. British Journal of Cancer, 2004, 90, 515-521.	6.4	51
119	A novel 1p36.2 located gene, APITD1, with tumour-suppressive properties and a putative p53-binding domain, shows low expression in neuroblastoma tumours. British Journal of Cancer, 2004, 91, 1119-1130.	6.4	21
120	Investigation of the role of SDHB inactivation in sporadic phaeochromocytoma and neuroblastoma. British Journal of Cancer, 2004, 91, 1835-1841.	6.4	43
121	Mutations in the N-terminal domain of DFF45 in a primary germ cell tumor and in neuroblastoma tumors. International Journal of Oncology, 2004, 25, 1297-302.	3.3	9
122	Epigenetic inactivation of the candidate 3p21.3 suppressor gene BLU in human cancers. Oncogene, 2003, 22, 1580-1588.	5.9	98
123	Screening for gene mutations in a 500â€‰kb neuroblastoma tumor suppressor candidate region in chromosome 1p; mutation and stage-specific expression in UBE4B/UFD2. Oncogene, 2003, 22, 2343-2351.	5.9	54
124	Nuclear accumulation of full-length and truncated adenomatous polyposis coli protein in tumor cells depends on proliferation. Oncogene, 2003, 22, 6013-6022.	5.9	24
125	Expression of trkB in Human Neuroblastoma in Relation to MYCN Expression and Retinoic Acid Treatment. Laboratory Investigation, 2003, 83, 813-823.	3.7	62
126	Quality Assessment of Genetic Markers Used for Therapy Stratification. Journal of Clinical Oncology, 2003, 21, 2077-2084.	1.6	113

#	Article	IF	Citations
127	Myosin heavy chain IIa gene mutation E706K is pathogenic and its expression increases with age. Neurology, 2002, 58, 780-786.	1.1	56
128	Identification of a Psoriasis Susceptibility Candidate Gene by Linkage Disequilibrium Mapping with a Localized Single Nucleotide Polymorphism Map. Genomics, 2002, 79, 305-314.	2.9	99
129	Analyses of apoptotic regulators CASP9 and DFFA at 1P36.2, reveal rare allele variants in human neuroblastoma tumours. British Journal of Cancer, 2002, 86, 596-604.	6.4	36
130	Foxe3 haploinsufficiency in mice: a model for Peters' anomaly. Investigative Ophthalmology and Visual Science, 2002, 43, 1350-7.	3.3	68
131	Periampullary adenomas and adenocarcinomas in familial adenomatous polyposis: Cumulative risks and APC gene mutations. Gastroenterology, 2001, 121, 1127-1135.	1.3	235
132	Essential fatty acid deficiency in relation to genotype in patients with cystic fibrosis. Journal of Pediatrics, 2001, 139, 650-655.	1.8	163
133	A founder mutation of the BRCA1 gene in Western Sweden associated with a high incidence of breast and ovarian cancer. European Journal of Cancer, 2001, 37, 1904-1909.	2.8	54
134	MECP2 mutation screening in Swedish classical Rett syndrome females. European Child and Adolescent Psychiatry, 2001, 10, 117-121.	4.7	20
135	Absence of somatostatin receptor expression in vivo is correlated to di- or tetraploid 1p36-deleted neuroblastomas. Medical and Pediatric Oncology, 2001, 36, 56-60.	1.0	5
136	Fine mapping of a tumour suppressor candidate gene region in 1p36.2-3, commonly deleted in neuroblastomas and germ cell tumours. Medical and Pediatric Oncology, 2001, 36, 61-66.	1.0	31
137	Scandinavian CDG-Ia patients: genotype/phenotype correlation and geographic origin of founder mutations. Human Genetics, 2001, 108, 359-367.	3.8	34
138	The western Swedish BRCA1 founder mutation 3171ins5; a 3.7â€‰cM conserved haplotype of today is a reminiscence of a 1500-year-old mutation. European Journal of Human Genetics, 2001, 9, 787-793.	2.8	50
139	Genome-wide linkage analysis of Scandinavian affected sib-pairs supports presence of susceptibility loci for celiac disease on chromosomes 5 and 11. European Journal of Human Genetics, 2001, 9, 938-944.	2.8	80
140	RASSF1A promoter region CpG island hypermethylation in phaeochromocytomas and neuroblastoma tumours. Oncogene, 2001, 20, 7573-7577.	5.9	127
141	Combined111In-pentetreotide scintigraphy and123I-mIBG scintigraphy in neuroblastoma provides prognostic information. Medical and Pediatric Oncology, 2000, 35, 688-691.	1.0	48
142	Mutations in PMM2 that cause congenital disorders of glycosylation, type Ia (CDG-Ia). Human Mutation, 2000, 16, 386-394.	2.5	136
143	PMM2 mutation spectrum, including 10 novel mutations, in a large CDG type 1A family material with a focus on Scandinavian families. Human Mutation, 2000, 16, 395-400.	2.5	27
144	S Gene (Corneodesmosin) Diversity and its Relationship to Psoriasis; High Content of cSNP in the HLA-Linked S Gene. Journal of Investigative Dermatology, 2000, 114, 1158-1163.	0.7	25

#	Article	IF	Citations
145	The CTLA4/CD28 gene region on chromosome 2q33 confers susceptibility to celiac disease in a way possibly distinct from that of type 1 diabetes and other chronic inflammatory disorders. Tissue Antigens, 2000, 56, 350-355.	1.0	98
146	Multiple mitochondrial DNA deletions in hereditary inclusion body myopathy. Acta Neuropathologica, 2000, 100, 23-28.	7.7	17
147	Stronger association with HLA-Cw6 than with corneodesmosin (S-gene) polymorphisms in Swedish psoriasis patients. Archives of Dermatological Research, 2000, 292, 525-530.	1.9	27
148	Autosomal dominant myopathy: Missense mutation (Glu-706 right-arrow Lys) in the myosin heavy chain IIa gene. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 14614-14619.	7.1	149
149	Patched 2, located in 1p32-34, is not mutated in high stage neuroblastoma tumors.. International Journal of Oncology, 2000, 16, 943-9.	3.3	1
150	Fine mapping of the human preprocortistatin gene (CORT) to neuroblastoma consensus deletion region 1p36.3â†'p36.2, but absence of mutations in primary tumors. Cytogenetic and Genome Research, 2000, 89, 62-66.	1.1	29
151	Denaturing High-Performance Liquid Chromatography Is a Suitable Method for PMM2 Mutation Screening in Carbohydrate-Deficient Glycoprotein Syndrome Type IA Patients. Genetic Testing and Molecular Biomarkers, 2000, 4, 293-297.	1.7	8
152	A Founder Mutation of the BRCA1-Gene in Western Sweden. Disease Markers, 1999, 15, 99-99.	1.3	0
153	Variable expression and absence of mutations in p73 in primary neuroblastoma tumors argues against a role in neuroblastoma development.. International Journal of Molecular Medicine, 1999, 3, 585-9.	4.0	16
154	Cytogenetic analysis of 477 psoriatics revealed an increased frequency of aberrations involving chromosome region 11q. European Journal of Human Genetics, 1999, 7, 339-344.	2.8	6
155	Psoriasis susceptibility locus in chromosome region 3q21 identified in patients from southwest Sweden. European Journal of Human Genetics, 1999, 7, 783-790.	2.8	131
156	Gain of chromosome arm 17q is associated with unfavourable prognosis in neuroblastoma, but does not involve mutations in the somatostatin receptor 2 (SSTR2) gene at 17q24. British Journal of Cancer, 1999, 81, 1402-1409.	6.4	46
157	The use of fine-needle aspiration cytology in the molecular characterization of neuroblastoma in children. Cancer, 1999, 87, 60-68.	4.1	37
158	Dominant Hereditary Inclusion-Body Myopathy Gene (IBM3) Maps to Chromosome Region 17p13.1. American Journal of Human Genetics, 1999, 64, 1420-1426.	6.2	47
159	A genome-wide search for genes predisposing to familial psoriasis by using a stratification approach. Human Genetics, 1999, 105, 523-529.	3.8	101
160	Analysis of Three Suggested Psoriasis Susceptibility Loci in a Large Swedish Set of Families: Confirmation of Linkage to Chromosome 6p (HLA Region), and to 17q, but not to 4q. Human Heredity, 1999, 49, 2-8.	0.8	73
161	The use of fineâ€needle aspiration cytology in the molecular characterization of neuroblastoma in children. Cancer, 1999, 87, 60-68.	4.1	2
162	A genome-wide search for genes predisposing to familial psoriasis by using a stratification approach. Human Genetics, 1999, 105, 523-529.	3.8	47

#	Article	IF	Citations
163	The use of fine-needle aspiration cytology in the molecular characterization of neuroblastoma in children. Cancer, 1999, 87, 60-8.	4.1	5
164	Beneficial effects of ropivacaine in rat experimental colitis. Journal of Pharmacology and Experimental Therapeutics, 1999, 291, 642-7.	2.5	14
165	Detailed mapping of the phosphomannomutase 2 (PMM2) gene and mutation detection enable improved analysis for Scandinavian CDG type I families. European Journal of Human Genetics, 1998, 6, 603-611.	2.8	31
166	Autosomal dominant myopathy with congenital joint contractures, ophthalmoplegia, and rimmed vacuoles. Annals of Neurology, 1998, 44, 242-248.	5.3	79
167	Loss of heterozygosity of 3p markers in neuroblastoma tumours implicate a tumour-suppressor locus distal to the FHIT gene. British Journal of Cancer, 1998, 77, 1787-1791.	6.4	61
168	Failure of shortâ€term mannose therapy of patients with carbohydrateâ€deficient glycoprotein syndrome type 1A. Acta Paediatrica, International Journal of Paediatrics, 1998, 87, 884-888.	1.5	48
169	Failure of short-term mannose therapy of patients with carbohydrate-deficient glycoprotein syndrome type 1A. Acta Paediatrica, International Journal of Paediatrics, 1998, 87, 884-888.	1.5	42
170	A large deletion disrupts the exon 3 transcription activation domain of the BRCA2 gene in a breast/ovarian cancer family. Cancer Research, 1998, 58, 1372-5.	0.9	61
171	Novel germline mutations in Swedish von Hippel-Lindau disease patients. International Journal of Oncology, 1997, 11, 509-12.	3.3	1
172	Fine Mapping of the Gene for Carbohydrate-Deficient Glycoprotein Syndrome, Type I (CDG1): Linkage Disequilibrium and Founder Effect in Scandinavian Families. Genomics, 1997, 39, 247-253.	2.9	50
173	Representational difference analysis and loss of heterozygosity studies detect 3p deletions in neuroblastoma. European Journal of Cancer, 1997, 33, 1966-1970.	2.8	21
174	Delimitation of a critical tumour suppressor region at distal 1p in neuroblastoma tumours. European Journal of Cancer, 1997, 33, 1997-2001.	2.8	49
175	Significantly Earlier Age at Onset for the HLA-Cw6-positive than for the Cw6-Negative Psoriatic Sibling. Journal of Investigative Dermatology, 1997, 109, 695-696.	0.7	23
176	Homozygous deletion of the neurofibromatosis-1 gene in the tumor of a patient with neuroblastoma. Cancer Genetics and Cytogenetics, 1997, 95, 183-189.	1.0	39
177	Structural and immunochemical identification of Le(a), Le(b), H type 1, and related glycolipids in small intestinal mucosa of a group O Le(a-b-) nonsecretor. Glycoconjugate Journal, 1997, 14, 209-223.	2.7	21
178	Genetic counselling in psoriasis: empirical data on psoriasis among first-degree relatives of 3095 psoriatic probands. British Journal of Dermatology, 1997, 137, 939-942.	1.5	27
179	Genetic counselling in psoriasis: empirical data on psoriasis among first-degree relatives of 3095 psoriatic probands. British Journal of Dermatology, 1997, 137, 939-942.	1.5	30
180	Genetic counselling in psoriasis: empirical data on psoriasis among first-degree relatives of 3095 psoriatic probands. British Journal of Dermatology, 1997, 137, 939-42.	1.5	10

#	Article	IF	Citations
181	Evidence that HLA-Cw6 determines early onset of psoriasis, obtained using sequence-specific primers (PCR-SSP).. Acta Dermato-Venereologica, 1997, 77, 273-276.	1.3	57
182	No genetic linkage between multiple sclerosis and the interferon Î±Î² locus. Journal of Neuroimmunology, 1996, 65, 163-165.	2.3	11
183	Report of the Sixth International Workshop on Human Chromosome 3 Mapping 1995. Cytogenetic and Genome Research, 1996, 72, 255-270.	1.1	17
184	Maternal origin of inv dup(15) chromosomes in infantile autism. European Child and Adolescent Psychiatry, 1996, 5, 185-192.	4.7	39
185	Analysis of location and integrity of the human PITSLRE (p58(cdc2L1)) genes in neuroblastoma cell genomes. International Journal of Oncology, 1996, 8, 1137-42.	3.3	2
186	Age at onset and different types of psoriasis. British Journal of Dermatology, 1995, 133, 768-773.	1.5	106
187	Localization of a gene for autosomal dominant Larsen syndrome to chromosome region 3p21.1-14.1 in the proximity of, but distinct from, the COL7A1 locus. American Journal of Human Genetics, 1995, 57, 1104-13.	6.2	26
188	Deletion of chromosome 1p loci and microsatellite instability in neuroblastomas analyzed with short-tandem repeat polymorphisms. Cancer Research, 1995, 55, 5681-6.	0.9	95
189	Dilated cardiomyopathy and the dystrophin gene: an illustrated review.. Heart, 1994, 72, 344-348.	2.9	43
190	HLA and prognosis in multiple sclerosis. Journal of Neurology, 1994, 241, 385-390.	3.6	63
191	Progress in a genome scan for linkage in schizophrenia in a large Swedish kindred. American Journal of Medical Genetics Part A, 1994, 54, 51-58.	2.4	45
192	A population genetic study of psoriasis. British Journal of Dermatology, 1994, 131, 32-39.	1.5	94
193	Duchenne muscular dystrophy and spinal muscular atrophy type I segregating in the same family. Clinical Genetics, 1994, 45, 97-103.	2.0	2
194	Linkage of a locus for carbohydrate-deficient glycoprotein syndrome type I (CDG1) to chromosome 16p, and linkage disequilibrium to microsatellite marker D16S406. Human Molecular Genetics, 1994, 3, 2037-42.	2.9	42
195	Successful DNA-based prenatal exclusion of juvenile neuronal ceroid lipofuscinosis. Prenatal Diagnosis, 1993, 13, 651-657.	2.3	8
196	Localization of the Human Tripeptidyl Peptidase II Gene (TPP2) to 13q32-q33 by Nonradioactive in Situ Hybridization and Somatic Cell Hybrids. Genomics, 1993, 17, 493-495.	2.9	9
197	Frequency of four cystic fibrosis mutations in a Swedish population. Acta Paediatrica, International Journal of Paediatrics, 1993, 82, 609-609.	1.5	9
198	Characterization of four melanoma cell lines with electron microscopy, immunocytochemistry, cytogenetics, flow cytometry, and southern analysis. Cancer Genetics and Cytogenetics, 1992, 62, 111-123.	1.0	9

#	Article	IF	Citations
199	Genomic organization and chromosomal localization of the human CTP synthetase gene (CTPS). Genomics, 1991, 11, 1088-1096.	2.9	13
200	Case Study: Autism Associated with Marker Chromosome. Journal of the American Academy of Child and Adolescent Psychiatry, 1991, 30, 489-494.	0.5	103
201	Analysis of Chromosome Band Ip36 Alterations by Chromosomal In Situ Suppression Hybridization With a Microclone DNA Bank. Genes Chromosomes and Cancer, 1991, 3, 407-410.	2.8	4
202	Chromosome I deletions in human neuroblastomas: Generation and fine mapping of microclones from the distal Ip region. Genes Chromosomes and Cancer, 1989, 1, 67-78.	2.8	62
203	Neuroblastoma consensus deletion maps to 1p36.1â€“2. Genes Chromosomes and Cancer, 1989, 1, 159-166.	2.8	166
204	Cytogenetic and molecular analysis of distal 1p deletion breakpoints in neuroblastomas. Cancer Genetics and Cytogenetics, 1989, 41, 217-218.	1.0	0
205	Classical and experimental cytogenetics in the study of human neuroblastomas, and fine mapping of 19 DNA probes in chr. 1. Cancer Genetics and Cytogenetics, 1989, 41, 267.	1.0	0
206	Tumorigenicity of SEWA murine cells correlates with degree of c-myc amplification. Oncogene, 1988, 3, 437-41.	5.9	18
207	Localization of the multidrug resistance-associated 170 kDa P-glycoprotein gene to mouse chromosome 5 and to homogeneously staining regions in multidrug-resistant mouse cells by in situ hybridization. Cytogenetic and Genome Research, 1987, 45, 99-101.	1.1	33
208	5 Persistence of fragmented mouse HSR chromatin in mouse-chinese hamster somatic cell hybrids resistant to actinomycin D. Cancer Genetics and Cytogenetics, 1987, 28, 29.	1.0	0
209	Novel cytogenetic expression of gene amplification in actinomycin D-resistant somatic cell hybrids: transfer of resistance by centric chromatin bodies. Chromosoma, 1987, 95, 408-418.	2.2	9
210	Characterization of multidrug resistance in SEWA mouse tumor cells: increased glutathione transferase activity and reversal of resistance with verapamil. Anticancer Research, 1987, 7, 65-9.	1.1	23
211	Pleiotropic drug resistance, protein overexpression, and cytogenetic signs of gene amplification in mouse tumor cells. Anticancer Research, 1986, 6, 579-81.	1.1	2
212	Amplification and enhanced expression of the c-myc oncogene in mouse SEWA tumour cells. Nature, 1985, 315, 345-347.	27.8	71
213	Pleiotropic drug resistance and gene amplification in a SEWA mouse tumor cell line. Experimental Cell Research, 1985, 158, 382-394.	2.6	35
214	Resistance to actinomycin D and to vincristine induced in a SEWA mouse tumor cell line with concomitant appearance of double minutes and a low molecular weight protein. Experimental Cell Research, 1984, 152, 415-426.	2.6	28
215	Gene amplification in mouse tumor cell lines. Cell Biology International Reports, 1981, 5, 772.	0.6	1
216	11q Deletion or ALK Activity Curbs DLG2 Expression to Maintain an Undifferentiated State in Neuroblastoma. SSRN Electronic Journal, 0, , .	0.4	0